Sunniyat Rahman
@minimolecule.bsky.social
Senior Postdoc at Dawson Lab, Peter Mac & Hon. Senior Research Fellow at UCL Cancer Institute | non-genetic resistance, gene regulation, and non-coding mutations in cancer
bit.ly/3B0wvaA - Google Scholar
Narrm (Melbourne)/London
bit.ly/3B0wvaA - Google Scholar
Narrm (Melbourne)/London
Pinned
Sunniyat Rahman
@minimolecule.bsky.social
· Dec 10
For my new followers! Focal deletions of noncoding regions in cancer genomes can have unexpected consequences. Out now in @bloodjournal.bsky.social, we’ve discovered a novel mechanism of oncogene activation whereby focal deletion of a ‘promoter tether’ leads to aberrant expression of IRX3 in T-ALL.👇
Reposted by Sunniyat Rahman
Starting off my bluesky journey by sharing my paper published this week: CD21 targeted CAR-T cells for the treatment of T-ALL.
The result of many years of work from many people. Funded by #CRUK #UKRI MRC and #GOSHCC
www.science.org/doi/10.1126/...
The result of many years of work from many people. Funded by #CRUK #UKRI MRC and #GOSHCC
www.science.org/doi/10.1126/...
Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia
Fratricide-resistant anti-CD21 CAR-T cells are effective in preclinical models of T cell acute lymphoblastic leukemia (T-ALL).
www.science.org
April 17, 2025 at 6:32 PM
Starting off my bluesky journey by sharing my paper published this week: CD21 targeted CAR-T cells for the treatment of T-ALL.
The result of many years of work from many people. Funded by #CRUK #UKRI MRC and #GOSHCC
www.science.org/doi/10.1126/...
The result of many years of work from many people. Funded by #CRUK #UKRI MRC and #GOSHCC
www.science.org/doi/10.1126/...
My previous mentor and great friend Prof. Marc Mansour from UCL has joined Bluesky! 🎉 Do consider following him if you’re researching acute leukaemias and associated novel therapies!
bsky.app/profile/marc...
bsky.app/profile/marc...
bsky.app
January 6, 2025 at 9:48 AM
My previous mentor and great friend Prof. Marc Mansour from UCL has joined Bluesky! 🎉 Do consider following him if you’re researching acute leukaemias and associated novel therapies!
bsky.app/profile/marc...
bsky.app/profile/marc...
Reposted by Sunniyat Rahman
Check out our new pre-print!
Exciting times ahead for Menin biology and targeting epigenetics regulators in AML.
Congratulations to all involved!
Exciting times ahead for Menin biology and targeting epigenetics regulators in AML.
Congratulations to all involved!
Thrilled to share a wonderful collaboration with Scott Armstrong, Florian Perner & Shellaina Gordon - exciting times ahead!
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia
Understanding the molecular pathogenesis of MLL fusion oncoprotein (MLL-FP) leukaemia has spawned epigenetic therapies that have improved clinical outcomes in this often-incurable disease. Using genet...
www.biorxiv.org
December 15, 2024 at 11:48 PM
Check out our new pre-print!
Exciting times ahead for Menin biology and targeting epigenetics regulators in AML.
Congratulations to all involved!
Exciting times ahead for Menin biology and targeting epigenetics regulators in AML.
Congratulations to all involved!
For my new followers! Focal deletions of noncoding regions in cancer genomes can have unexpected consequences. Out now in @bloodjournal.bsky.social, we’ve discovered a novel mechanism of oncogene activation whereby focal deletion of a ‘promoter tether’ leads to aberrant expression of IRX3 in T-ALL.👇
December 10, 2024 at 10:35 AM
For my new followers! Focal deletions of noncoding regions in cancer genomes can have unexpected consequences. Out now in @bloodjournal.bsky.social, we’ve discovered a novel mechanism of oncogene activation whereby focal deletion of a ‘promoter tether’ leads to aberrant expression of IRX3 in T-ALL.👇
Reposted by Sunniyat Rahman
Plugging our new paper on the new platform: “Unravelling mutational signatures with plasma circulating tumour DNA”
Peter Mac researchers unveil MisMatchFinder, a blood test that profiles cancer by analysing DNA changes, helping to personalise treatment faster & without invasive biopsies.
Read about this breakthrough in @naturecomms.bsky.social, today's Herald Sun or here: www.petermac.org/about-us/new...
Read about this breakthrough in @naturecomms.bsky.social, today's Herald Sun or here: www.petermac.org/about-us/new...
December 6, 2024 at 7:15 AM
Plugging our new paper on the new platform: “Unravelling mutational signatures with plasma circulating tumour DNA”
Reposted by Sunniyat Rahman
Let's build a starter pack for childhood cancer research.
Please send a message to be added! 🎗️
go.bsky.app/Tpd9QnM
Please send a message to be added! 🎗️
go.bsky.app/Tpd9QnM
November 24, 2024 at 3:27 PM
Let's build a starter pack for childhood cancer research.
Please send a message to be added! 🎗️
go.bsky.app/Tpd9QnM
Please send a message to be added! 🎗️
go.bsky.app/Tpd9QnM
Reposted by Sunniyat Rahman
Peter Mac is excited to join BlueSky! 🦋 We look forward to sharing ideas, fostering positivity, and connecting with you all as we work together to advance cancer care and research. Let’s inspire, collaborate, and make a difference!
November 21, 2024 at 12:23 AM
Peter Mac is excited to join BlueSky! 🦋 We look forward to sharing ideas, fostering positivity, and connecting with you all as we work together to advance cancer care and research. Let’s inspire, collaborate, and make a difference!
Reposted by Sunniyat Rahman
A social media platform where likeminded individuals (not trolls or imbeciles) interact to share their latest ideas, discoveries and news - Looking forward to this!
November 18, 2024 at 9:01 AM
A social media platform where likeminded individuals (not trolls or imbeciles) interact to share their latest ideas, discoveries and news - Looking forward to this!
Reposted by Sunniyat Rahman
Looking forward to joining the Bluesky community- glad to have made the move!
November 18, 2024 at 9:01 AM
Looking forward to joining the Bluesky community- glad to have made the move!
Hey scientists/academics👋, I’m moving over. Looking to follow researchers working on gene regulation, epigenetics, lineage tracing, non-coding mutations, single cell techniques, and drug resistance in cancer - let’s follow each other 😄
November 14, 2024 at 9:13 AM
Hey scientists/academics👋, I’m moving over. Looking to follow researchers working on gene regulation, epigenetics, lineage tracing, non-coding mutations, single cell techniques, and drug resistance in cancer - let’s follow each other 😄